Jump to content


Photo

The survivors: How an experimental treatment saved patients and changed medicine


  • Please log in to reply
8 replies to this topic

#1 r06ue1

r06ue1

    Advanced Member

  • Members
  • PipPipPip
  • 426 posts
  • LocationEarth, Solar System, Milky Way, Local Group, Virgo Supercluster, Laniakea

Posted 26 April 2017 - 05:38 AM

 

In January 1999, a new round of patients, all with chronic myeloid leukemia (CML) drove the wooded, winding road to Druker's hilltop clinic, with views ...

 

The survivors: How an experimental treatment saved patients and changed medicine

https://www.statnews...dicine-gleevec/

 

 

 


08/2015 Initial PCR: 66.392%

12/2015 PCR: 1.573%

03/2016 PCR: 0.153%

06/2016 PCR: 0.070%

09/2016 PCR: 0.052%

12/2016 PCR: 0.036%

03/2017 PCR: 0.029%

06/2017 PCR: 0.028%

09/2017 PCR: 0.025%

12/2017 PCR: 0.018%

 

 

Taking Imatinib 400 mg


#2 hannibellemo

hannibellemo

    Advanced Member

  • Members
  • PipPipPip
  • 728 posts
  • LocationNorth Central Iowa

Posted 26 April 2017 - 08:13 AM

What a great read! Thanks for posting this, r06ue1.


Pat

 

"You can't change the direction of the wind but you can adjust your sails."

DX 12/08; Gleevec 400mg; liver toxicity; Sprycel 100mg.; CCyR 4/10; MMR 8/10; Pleural Effusion 2/12; Sprycel 50mg. Maintaining MMR; 2/15 PCRU; 8/16 drifting in and out of undetected like a wave meeting the shore. Retired 12/23/2016! 18 months of PCRU, most recent at Mayo on 7/25/17 was negative at their new sensitivity reporting of 0.003.<p>


#3 Red Cross Kirk

Red Cross Kirk

    Advanced Member

  • Members
  • PipPipPip
  • 173 posts
  • LocationOregon

Posted 26 April 2017 - 11:17 AM

I wish reporters would be more accurate. For example, and I quote:

 

"Unlike the others before them, their cancer disappeared. And, for a vast majority, it never came back."

 

I'm still waiting for my cancer to disappear, as are most of us who have CML.  I think it would be more accurate to say "... was controlled." than to say "...disappeared."  But maybe I'm a little too close to the subject to be objective about it. <_<


Kirk

 

9/25/2012  p210 transcript 118.7% IS @ Dx, begin Gleevec 400mg/day
12/2012  3.59% & bone marrow biopsy - no residual myeloproliferative features but detected 1/20 metaphases containing the Philadelphia chromosome
2013  0.914%, 0.434%, 0.412%
10/2013  0.360% & bone marrow biopsy - normal male karyotype with no evidence of a clonal cytogenetic abnormaltiy
2014  0.174%, 0.088%, 0.064%

2015  0.049%, decrease to Gleevec 200mg/day, 0.035%, 0.061%, 0.028%

2016  0.041%, 0.039%, 0.025%

2017  0.029%, 0.039%, switched to generic imatinib 200mg/day, 0.070%, 0.088%

2018  0.233%


#4 Pin

Pin

    Advanced Member

  • Members
  • PipPipPip
  • 202 posts

Posted 26 April 2017 - 04:51 PM

Yeah, it's often written about in that way, but I have to wonder if maybe it was accurate for back then? The testing equipment wouldn't have been as sensitive as today, so it probably really did look like it disappeared! :)

Diagnosed 9 June 2011, Glivec 400mg June 2011-July 2017, Tasigna 600mg July 2017-present (switched due to intolerable side effects, and desire for future cessation attempt).

Commenced monthly testing when MR4.0 lost during 2012.

 

2017: <0.01, <0.01, 0.005 (200mg Glivec, Adelaide) <0.01, 0.001 (new test sensitivity)

2016: <0.01, <0.01, PCRU, 0.002 (Adelaide)

2015: <0.01, <0.01, <0.01, 0.013

2014: PCRU, <0.01, <0.01, <0.01, <0.01

2013: 0.01, 0.014, 0.016, 0.026, 0.041, <0.01, <0.01 

2012: <0.01, <0.01, 0.013, 0.032, 0.021

2011: 38.00, 12.00, 0.14


#5 Pin

Pin

    Advanced Member

  • Members
  • PipPipPip
  • 202 posts

Posted 26 April 2017 - 04:52 PM

Thanks for the read r06ue1!

Diagnosed 9 June 2011, Glivec 400mg June 2011-July 2017, Tasigna 600mg July 2017-present (switched due to intolerable side effects, and desire for future cessation attempt).

Commenced monthly testing when MR4.0 lost during 2012.

 

2017: <0.01, <0.01, 0.005 (200mg Glivec, Adelaide) <0.01, 0.001 (new test sensitivity)

2016: <0.01, <0.01, PCRU, 0.002 (Adelaide)

2015: <0.01, <0.01, <0.01, 0.013

2014: PCRU, <0.01, <0.01, <0.01, <0.01

2013: 0.01, 0.014, 0.016, 0.026, 0.041, <0.01, <0.01 

2012: <0.01, <0.01, 0.013, 0.032, 0.021

2011: 38.00, 12.00, 0.14


#6 Red Cross Kirk

Red Cross Kirk

    Advanced Member

  • Members
  • PipPipPip
  • 173 posts
  • LocationOregon

Posted 26 April 2017 - 07:20 PM

I finally had time to read the whole article and this sentence struck me:

 

"I had a bone marrow biopsy. I've had 70 of them."

 

WOW!!  Thank you Gleevec pioneers!


Kirk

 

9/25/2012  p210 transcript 118.7% IS @ Dx, begin Gleevec 400mg/day
12/2012  3.59% & bone marrow biopsy - no residual myeloproliferative features but detected 1/20 metaphases containing the Philadelphia chromosome
2013  0.914%, 0.434%, 0.412%
10/2013  0.360% & bone marrow biopsy - normal male karyotype with no evidence of a clonal cytogenetic abnormaltiy
2014  0.174%, 0.088%, 0.064%

2015  0.049%, decrease to Gleevec 200mg/day, 0.035%, 0.061%, 0.028%

2016  0.041%, 0.039%, 0.025%

2017  0.029%, 0.039%, switched to generic imatinib 200mg/day, 0.070%, 0.088%

2018  0.233%


#7 tiredblood

tiredblood

    Advanced Member

  • Members
  • PipPipPip
  • 474 posts

Posted 26 April 2017 - 08:54 PM

Enjoyed reading that. Thanks for posting.

#8 AdamJ

AdamJ

    Advanced Member

  • Members
  • PipPipPip
  • 65 posts
  • LocationTokyo, Japan

Posted 27 April 2017 - 10:01 AM

Thanks for sharing that article. I have always considered myself "lucky" to have received this diagnosis now rather than 20+ years ago, but I never gave enough thought to those who paved the way for the current treatment options.  While it is true that there can be difficult side effects and the drug companies are certainly unethically exploiting us, at least we can survive to be troubled by these things.  Those patients thought they were on borrowed time and from their perspective a miracle took place with those drug trials.  I hope as time passes, people with a larger variety of cancers can experience the same thing.


3/23/2016 Dx PCR 93.4399% IS, FISH 87%
3/30/16 Sprycel 100mg
4/15/2016 liver toxicity and a brief stint on Tasigna 600mg book-ended by drug breaks
6/6/2016 resumed Sprycel at 50 mg increased to 70 one month later followed by 100mg
6/17/2016 FISH Test 2%
8/22/2016 PCR 0.0035% IS
11/7/2016 PCRU
12/29/2016 PCRU
4/5/2017 PCRU
6/28/2017 PCRU
10/26/2017 PCRU


#9 Gail's

Gail's

    Advanced Member

  • Members
  • PipPipPip
  • 634 posts

Posted 27 April 2017 - 10:33 AM

We've heard about the science behind Gleevec's use, but how touching to hear the stories of those whose lives were extended by this drug. Very encouraging!
Diagnosed 1/15/15
FISH 92%
BMB 9:22 translocation
1/19/15 began 400 mg gleevec
1/22/15 bcr 37.2 IS
2/6/15 bcr 12.5 IS
3/26/15 bcr 10.3 IS
6/29/15 bcr 7.5 IS
9/24/15 bcr 0.8 IS
1/4/16 bcr 0.3 IS
Started 100 mg dasatinib, mutation analysis negative
4/20/16 bcr 0.03 IS
8/8/16 bcr 0.007 IS
12/6/16 bcr 0.002 IS
Lowered dasatinib to 70 mg
4/10/17 bcr 0.001 IS
Lowered dasatinib to 50 mg
7/5/17 bcr 0.004 IS
8/10/17 bcr 0.001. Stopped TKI in prep for September surgery.
9/10/17 bcr 0.006
10/10/17 bcr 0.088




1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users